08:00 | Registration |
|
Session Title: Why are Organs-on-Chip Attractive Proxies for Drug Discovery and Toxicity Screening? |
| Session Chair: John Greenman, Professor of Tumour Immunology, The University Of Hull, United Kingdom |
| |
09:00 |  | Keynote Presentation Organ-on-a-chip – Are We There Yet?
Lars Sundstrom, Professor of Practice in Translational Medicine, Elizabeth Blackwell Institute for Health Research, Bristol University, United Kingdom
It was suggested over a decade ago that the ERA of Flat Biology (2D Tissue culture) would soon be over and that 3 dimensional ‘Organotypic’ systems would become the dominant in-vitro model for drug profiling. While we have made huge technical advances in methods of producing reliable 3D systems from both Stem Cells and Primary tissues these are not yet mainstream. Along with advances in microfluidics we could be equally bold and suggest the time has come for new ‘Organ on a Chip’ systems to replace in-vivo alternatives. In this presentation I’d like to explore translational aspects and explore where barriers still exist that might inhibit up take of such systems and prevent their widespread acceptance by the research community and by Industry. |
|
09:45 | Towards Organs-on-Chip for Drug Testing, Mechanistic Studies, and Personalized Medicine by Selective Assembly of Primary Cells Enabled by Dielectrophoresis in Microfluidic Devices
Martin Stelzle, Head of BioMEMS & Sensors Department, NMI at University of Tübingen, Germany
Organs-on-chip are envisioned to provide in vivo-like results in preclinical drug testing by establishing cell cultures mimicking the smallest functional units of an organ. A brief review of prominent international projects will be given. Secondly, we will report on our organs-on-chip technology based on combining microfluidics and dielectrophoresis (DEP) to assemble primary human cells and enabling the automated in vitro construction of micro-organs mimicking the in vivo structure of organs. |
10:15 | Modular Human Biochip-based Organoid Models in Biomedical Research
Alexander Mosig, Lab Head, Biochip-based Organ Models, Jena University Hospital, Germany
A novel biochip organoid platform involving circulating primary immune cells has been developed for the investigation of sepsis-related organ dysfunction. Organoid models are capable to mimic inflammation-related organ failure as well as essential aspects of of tissue repair. |
10:45 | Coffee & Networking in the Exhibition Hall |
11:15 |  | Keynote Presentation A UK Regulatory View on the Acceptability of Organ on a Chip Data
David Jones, Senior Scientific Advisor, Medicines and Healthcare Products Regulatory Agency, United Kingdom
I will give a UK Regulator’s view on the acceptability on in vitro data, especially data using human tissues and from organ on a chip assays. |
|
12:00 | Putting a Human Heart & Fat on a Chip: Microphysiological Platforms as in vitro Models of Cardiac and Adipose Tissue
Peter Loskill, Assistant Professor for Experimental Regenerative Medicine; Attract Group Leader Organ-on-a-Chip, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Eberhard Karls University Tübingen, Germany
Using microfabrication techniques we have developed two microphysiological platforms incorporating 3D in vitro models of human cardiac and adipose tissue in a microfluidic environment. Both organ-chips are able to create physiological micro-tissues that are viable and functional for multiple weeks. |
12:45 | Lunch & Networking in the Exhibition Hall |
13:30 | Poster Viewing Session |
|
Session Title: Organs-on-a-Chip - Research to Commercialisation |
| Session Chair: Lars Sundstrom, Professor of Practice in Translational Medicine, Elizabeth Blackwell Institute for Health Research, Bristol University, United Kingdom |
| |
14:15 | The Patent Landscape of Organs-on-a-chip
Robert Esmond, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C, United States of America
The presentation will focus on ways to protect organs-on-a-chip innovation, patent filings directed to organs-on-a-chip technology, certain exceptions to patent infringement, as well as the possibility of future litigation. |
14:45 | |
15:45 | Coffee & Networking in the Exhibition Hall |
16:15 |  | Keynote Presentation The Commercialisation of Organs-on-Chips: Case Study
David Hughes, Chief Technical Officer, CN Bio Innovations Ltd., United Kingdom
In this presentation I will discuss the development and commercialisation of CN Bio Innovation’s LiverChip platform together with Quantum B our full viral life cycle model of Hepatitis B infection and look ahead to opportunities for multi-organ systems. |
|
17:00 | Bioinks Supporting Angiogenic Potential in Organ Printing
Kalle Johnson, R&D Development Team Manager, GE Healthcare Services, United States of America
Michael Golway, President & CEO, Advanced Solutions, Inc., United States of America
One of the last hurdles in the bioprinting of larger tissues and full organs is the engineering of functional vascularization. The additive manufacturing of proto-vascular biomimetic structures has progressed but limitations still exist with achieving functional vascular systems capable of angiogenesis and differentiated structures that mimic the behavior in a living organism. One challenge remaining is the development of both appropriate printing fluids and the in vitro culture media employed in the progression of the pre-implantation 3D bioprinted scaffolds. |
17:30 | Commercial Development of Organ-on-a-chip Systems – Challenges and Strategies
Juliane Schnabel, Scientist Application, Microfluidic ChipShop GmbH, Germany
The transition from academic results into commercial development of organ-on-a-chip devices has specific challenges. In this paper, we present examples for organ-on-a-chip devices with respect to manufacturability and scalability. |
18:00 |  Drinks Reception in the Exhibition Hall
|
18:45 | End of Day One |
